Regional analysis of COPD exacerbation rates in the DYNAGITO trial Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007
Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies Source: Annual Congress 2010 - COPD: management Year: 2010
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Identifying risk factors affecting the first asthma exacerbation rate in a multi-centre study examining the use of salmeterol xinafoate/fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Determining SGRQ and TDI responder rates across the duration of clinical trials: Results from tiotropium + olodaterol in COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017
Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Effectiveness of early intervention with budesonide in mild persistent asthma — 5-year data from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Lower incidence of asthma exacerbations with FE NO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Safety of formoterol in asthma clinical trials Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012